SLC5A2 and acute kidney injury: Finally, in a pooled analysis of five trials investigating AKI, SGLT2 inhibitors significantly reduced the risk by 22% compared to the placebo (RR = 0.78, 95% CI: 0.67–0.89, I2 = 0%, Figure 3d).